Regulus Therapeutics Files For IPO

San Diego-based Regulus Therapeutics has filed for an IPO, saying that it is looking to raised up to $57.5M in an IPO on the NASDAQ Global Market. The developer of microDNA-based biopharmaceuticals said it hopes to trade as RGLS. The IPO is being underwritten by Lazard Capital Markets, Cowen and Company, BMO Capital Markets, Needham & Company and Wedbush PacGrow Life Sciences. Regulus Therapeutics is a spinout of Alnylam Pharmaceuticals and Isis Pharmaceuticals, which are the company's two largest shareholders; Aventis, Glaxo, and AstraZeneca also owns stakes in the firm.